Glenmark bullish on drug discovery pipeline, eyes partnerships
HYDERABAD: As many as six out of seven molecules in Glenmark’s drug discovery pipeline are currently in the clinical trial stage and the company’s R&D spend pegged at 10 per cent of sales is expected to be maintained at similar levels for next two years, a top official has said.
Pain, inflammation and oncology are the therapeutic areas currently the drug maker is working on, said Glenn Saldanha, Chairman & Managing Director, Glenmark PharmaceuticalsBSE 0.40 % Ltd.
“C ..